The overall safety profile of VOXZOGO in children under 5 years of age was similar to that seen in older children102023 805 PM US Food and Drug Administration Approves BioMarins VOXZOGO vosoritide for Children Under 5 Years with Achondroplasia  Oct 20  httpsinvestorsbiomarincom20231020USFoodandDrugAdministrationApprovesBioMarinsVOXZOGORvosoritideforChildrenUnder5Yearswith 311Data from an openlabel longterm Phase 2 extension study was recently presented at the 2023 European Society for Paediatric Endocrinology Meeting in September